SPIE and the University of Birmingham Establish $800,000 Photonics-focused Education Fund
30.9.2021 12:03:00 EEST | Business Wire | Press release
SPIE, the international society for optics and photonics, and the University of Birmingham have announced the establishment of the SPIE Optics and Photonics Champion Academy fund. The new endowment was announced this morning, during SPIE Photonex + Vacuum Technologies in Glasgow, Scotland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005066/en/
University of Birmingham students pictured in the UK Quantum Technology Hub, home to the SPIE Optics and Photonics Champions Academy. (Photo: Business Wire)
The $400,000 gift from the SPIE Endowment Matching Program will be matched 100% by the university, and the $800,000 fund will create and support the SPIE Optics and Photonics Champion Academy. The cohort-focused program will engage in areas of public interest in the fields of quantum technology and biomedical imaging and data sciences: one of the first projects will address pandemics. The program will be led by Professor and Principal Investigator of the UK Quantum Technology Hub Sensors and Timing Kai Bongs, and Professor of Computational Life Sciences Iain Styles.
The SPIE Optics and Photonics Champion Academy will support University of Birmingham students in a variety of ways which include expanding cross-disciplinary educational opportunities in optics and photonics; offering students hands-on support and training to become influential science communicators and advocates of optics and photonics; and by utilizing a range of stipends, awards, and activity grants, which will be supplemented with professional development and mentoring opportunities from the university’s academic leaders as well as from external experts.
The program will focus particularly on students in underrepresented groups, early-career researchers, and PhD students in order to establish and build a broad, diverse, and inclusive network of science advocates, especially in the area of optics and photonics.
“We are delighted to be able to work with SPIE to launch this unique Academy at the University of Birmingham,” said Professor Bongs. “This initiative will help to accelerate the growth of optics and photonics expertise, which will have great impact far beyond the university. Our hope is to not only encourage this learning, but to also create awareness of the huge importance of this subject area in tackling real-world problems.”
“By equipping early-career optics and photonics researchers and PhD students with skills in advanced data analysis, we will help to accelerate the translation of these exciting technologies from the laboratory to their adoption in real-world applications,” added Professor Styles. “Our SPIE Champions will be able to work with experts in diverse application areas such as healthcare and climate monitoring to develop end-to-end optics-based solutions with integrated analytics for some of our most pressing challenges.”
“By offering direct, experiential training in quantum technology and biomedical imaging as well as highlighting various career options in the field, the SPIE Optics and Photonics Champion Academy will develop a natural pipeline of future professional scientists and engineers in these fields,” noted SPIE President David Andrews. “And by encouraging students to actively raise awareness of the impact of optics and photonics to their contemporaries, peers, and younger colleagues, the program will be creating visible, engaged role models for future generations.”
The SPIE Endowment Matching Program was established in 2019 to increase international capacity in the teaching and research of optics and photonics, and to date has given more than $3.4 million in matching gifts, resulting in more than $9 million in dedicated funds. The SPIE Endowment Matching Program supports optics and photonics education and the future of the industry by contributing a match of up to $500,000 per award to college and university programs with optics and photonics degrees, or with other disciplines allied to the SPIE mission.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005066/en/
Contact information
Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
